Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
1. Psyrri A, et al. ESMO 2012 Congress; ESMO ID No: 1018O.
2. Vermorken JB, et al. N Engl J Med 2008;359:1116–27.
3. Mesia R, et al. Ann Oncol 2010;21(10):1967–73.
4. Westra WH. Head and Neck Pathol 2009;3:78–81.
For more information on Erbitux in colorectal and head & neck cancer, please visit: http://www.globalcancernews.com.
Erbitux® is a first-in-class and highly active IgG1 monoclonal antibody targeting the epidermal growth factor receptor (EGFR). As a monoclonal antibody, the mode of action of Erbitux is distinct from standard non-selective chemotherapy treatments in that it specifically targets and binds to the EGFR. This binding inhibits the activation of the receptor and the subsequent signal-transduction pathway, which results in reducing both the invasion of normal tissues by tumor cells and the spread of tumors to new sites. It is also believed to inhibit the ability of tumor cells to repair the damage caused by chemotherapy and radiotherapy and to inhibit the formation of new blood vessels inside tumors, which appears to lead to an overall suppression of tumor growth.
The most commonly reported side effect with Erbitux is an acne-like skin rash that seems to be correlated with a good response to therapy. In approximately 5% of patients, hypersensitivity reactions may occur during treatment with Erbitux; about half of these reactions are severe.
Erbitux has already obtained market authorization in 92 countries. It has been approved for the treatment of colorectal cancer in 92 countries and for the treatment of squamous cell carcinoma of the head and neck (SCCHN) in 89 countries.
Merck licensed the right to market Erbitux outside the US and Canada from ImClone LLC, a wholly-owned subsidiary of Eli Lilly and Company, in 1998. In Japan, ImClone, Bristol-Myers Squibb Company and Merck jointly develop and commercialize Erbitux. Merck has an ongoing commitment to the advancement of oncology treatment and is currently investigating novel therapies in highly targeted areas.
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Cancer / Oncology category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
Serono, Merck. "Erbitux Outcomes In Patients With Head And Neck Cancer Seem To Be Independent Of HPV Tumor Status." Medical News Today. MediLexicon, Intl., 3 Oct. 2012. Web.
23 Apr. 2014. <http://www.medicalnewstoday.com/releases/251008>
Serono, M. (2012, October 3). "Erbitux Outcomes In Patients With Head And Neck Cancer Seem To Be Independent Of HPV Tumor Status." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/251008.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2014 All rights reserved. MNT is the registered trade mark of MediLexicon International Limited.